Sugi Predict

Sugi Predict / Compounds / SCHEMBL1800915

SCHEMBL1800915

SCHEMBL1800915

CNc1nccc(C(OC)OC)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ MAPK9 P45984 2/20 0.41
▸ MAPK10 P53779 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ KMT2A Q03164 5/20 0.40
▸ MAPT P10636 3/20 0.40
▸ RAB9A P51151 2/20 0.39
▸ DYRK1A Q13627 1/20 0.34
▸ MAPK14 Q16539 2/20 0.33
▸ FLT3 P36888 2/20 0.33
▸ MAPK13 O15264 1/20 0.33
▸ RAF1 P04049 1/20 0.33
▸ MAPK12 P53778 1/20 0.33
▸ MAPK11 Q15759 1/20 0.33
▸ AURKA O14965 1/20 0.33
▸ TTK P33981 1/20 0.33
▸ AURKB Q96GD4 1/20 0.33
▸ INCENP Q9NQS7 1/20 0.33
▸ BRAF P15056 1/20 0.33
▸ KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7812263 0.84 SMN1; SMN2 (0.37) SMN1; SMN2MAPK9MAPK10L3MBTL1KMT2A
SCHEMBL12411162 0.82 MAPK8 (0.47) SMN1; SMN2MAPK9MAPK10L3MBTL1KMT2A
SCHEMBL84061 0.79 MAPK9 (0.43) MAPK9MAPK10DYRK1AMAPK14FLT3
SCHEMBL21797185 0.78 KMT2A (0.43) SMN1; SMN2MAPK9MAPK10L3MBTL1KMT2A
SCHEMBL4490400 0.78 AURKA (0.54) KMT2AMAPTRAB9AAURKAAURKB
SCHEMBL16815715 0.77 MKNK1 (0.47) SMN1; SMN2MAPK9L3MBTL1KMT2ARAB9A
SCHEMBL21797166 0.76 CDC7 (0.46) L3MBTL1KMT2AMAPTRAB9AMEN1
SCHEMBL2052150 0.76 MAPK9 (0.42) MAPK9MAPK10DYRK1AMAPK14FLT3
Hydrochloric Acid SCHEMBL29243489 0.76 MAPK9 (0.42) MAPK9MAPK10DYRK1AMAPK14FLT3
SCHEMBL2039982 0.76 MAPK9 (0.42) MAPK9MAPK10DYRK1AMAPK14FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3619204-B1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES TIANLI BIOTECH PTY LTD (AU) 2025-10-01 — — EP disclosed
US-20220380343-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES TIANLI BIOTECH PTY LTD (AU) 2022-12-01 — — US disclosed
WO-2022079226-A1 INHIBITORS OF PDEDELTA UNIVERSITÉ DU LUXEMBOURG (LU) 2022-04-21 — — WO disclosed
CN-108349896-B Heterocyclic compounds as FGFR inhibitors 南京天印健华医药科技有限公司 2021-06-01 — — CN disclosed
US-10590109-B2 Heterocyclic compounds used as FGFR inhibitors NANJING INNOCARE PHARMA TECH CO., LTD. (CN) 2020-03-17 — — US disclosed
US-10590109-B2 Heterocyclic compounds used as FGFR inhibitors NANJING INNOCARE PHARMA TECH CO., LTD. (CN) 2020-03-17 — — US disclosed
US-20200079757-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES THE UNIVERSITY OF MELBOURNE (AU) 2020-03-12 — — US disclosed
CN-110753688-A Compounds for the treatment of respiratory diseases 墨尔本大学 2020-02-04 — — CN disclosed
EP-3489223-A1 HETEROCYCLIC COMPOUND USED AS FGFR INHIBITOR Nanjing Innocare Pharma Tech Co., Ltd. (CN) 2019-05-29 — — EP disclosed
US-20190144427-A1 HETEROCYCLIC COMPOUNDS USED AS FGFR INHIBITORS NANJING INNOCARE PHARMA TECH CO., LTD. (CN) 2019-05-16 — — US disclosed
EP-1530568-A1 INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING I&kB KINASE Aventis Pharma Deutschland GmbH (DE) 2005-05-18 — — EP disclosed
EP-1519921-A2 SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE Amgen Inc. (US) 2005-04-06 — — EP disclosed
US-20040087568-A1 Substituted anthranilic amide derivatives and methods of use AMGEN INC. 2004-05-06 — — US disclosed
WO-2004022057-A1 USE OF IκB KINASE INHIBITORS FOR THE TREATMENT OF PAIN AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-03-18 — — WO disclosed
WO-2004022553-A1 INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IκB KINASE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-03-18 — — WO disclosed
WO-2004005279-A2 SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2004-01-15 — — WO disclosed
EP-1264827-A1 Process for the preparation of Tosylbenzylformamides SMITHKLINE BEECHAM CORPORATION (US) 2002-12-11 — — EP disclosed
EP-0809499-A4 CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE SMITHKLINE BEECHAM CORP (US) 1998-10-14 — — EP disclosed
EP-0809499-A1 CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE SMITHKLINE BEECHAM CORPORATION (US) 1997-12-03 — — EP disclosed
WO-1996021452-A1 CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE SMITHKLINE BEECHAM CORPORATION (US) 1996-07-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144427-A1 HETEROCYCLIC COMPOUNDS USED AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 SMN1; SMN2 2539/4885MAPK9 346/4885MAPK10 821/4885
US-10590109-B2 Heterocyclic compounds used as FGFR inhibitors FGFR1, FGFR3, FGFR2 SMN1; SMN2 2539/4885MAPK9 346/4885MAPK10 821/4885
US-20040087568-A1 Substituted anthranilic amide derivatives and methods of use AADAC, ASPH, EGLN3 SMN1; SMN2 3639/4885MAPK9 2006/4885MAPK10 2216/4885
US-20220380343-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES LTC4S, LTB4R2, LTB4R SMN1; SMN2 3328/4885MAPK9 4435/4885MAPK10 3409/4885
US-20200079757-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES LTC4S, LTB4R2, LTB4R SMN1; SMN2 3328/4885MAPK9 4435/4885MAPK10 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.